Table 2 Stratified analysis of risk of retinal vascualr occlusion exposed to COVID-19 vaccines compared with unvaccinated individuals in 2 years.

Age 18–64

506,701

506,701

Retinal vascular occlusion^b

415

240

1.87 (1.58–2.19)

 BRAO

95

63

1.65 (1.19–2.28)

 BRVO

174

86

2.21 (1.69–2.87)

 CRAO

45

34

1.47 (0.93–2.31)

 CRVO

156

78

2.19 (1.65–2.88)

Age ≥ 65

236,804

236,804

Retinal vascular occlusion^b

1108

520

2.37 (2.12–2.62)

 BRAO

251

140

2.07 (1.67–2.54)

 BRVO

443

180

2.70 (2.26–3.21)

 CRAO

136

89

1.74 (1.32–2.28)

 CRVO

390

169

2.55 (2.12–3.05)

Female

437,682

437,682

Retinal vascular occlusion^b

782

359

2.33 (2.05–2.64)

 BRAO

168

92

2.02 (1.56–2.61)

 BRVO

332

133

2.64 (2.15–3.23)

 CRAO

99

58

1.88 (1.34–2.60)

 CRVO

272

115

2.54 (2.04–3.16)

Male

302,269

302,269

Retinal vascular occlusion^b

731

328

2.40 (2.10–2.73)

 BRAO

178

92

2.17 (1.67–2.80)

 BRVO

277

104

2.81 (2.23–3.52)

 CRAO

87

55

1.69 (1.20–2.37)

 CRVO

266

104

2.79 (2.21–3.50)

White

545,223

545,223

Retinal vascular occlusion^b

1146

546

2.31 (2.08–2.55)

 BRAO

278

149

2.12 (1.72–2.59)

 BRVO

465

179

2.79 (2.34–3.31)

 CRAO

135

86

1.78 (1.35–2.34)

 CRVO

396

175

2.52 (2.10–3.01)

African American

89,833

89,833

Retinal vascular occlusion^b

218

118

2.05 (1.63–2.56)

 BRAO

40

25

1.85 (1.11–3.07)

 BRVO

84

42

2.18 (1.50–3.16)

 CRAO

37

19

2.14 (1.22–3.73)

 CRVO

83

41

2.28 (1.56–3.31)

Asian

26,080

26,080

Retinal vascular occlusion^b

40

16

2.62 (1.46–4.68)

 BRAO

<10^a

<10^a

1.93 (0.46–8.11)

 BRVO

22

<10^a

2.84 (1.25–6.39)

 CRAO

<10^a

<10^a

3.69 (0.41–33.00)

 CRVO

<10^a

<10^a

1.78 (0.64–4.93)